Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The phrase "Muscle tissue synthesis via provision of essential amino acids" does **not** refer to a specific molecule, receptor, enzyme, or canonical therapeutic target. Instead, it describes a physiological process whereby the availability and supplementation of **essential amino acids**—particularly leucine—stimulate **muscle protein synthesis**. This effect is primarily mediated through activation of the mammalian target of rapamycin (**mTOR**) signaling pathway. The process is central to maintaining and increasing skeletal muscle mass following resistance exercise or during recovery from illness/injury[1][3][7]. Essential amino acids are not synthesized by the body and must be obtained through diet; their presence is required for optimal rates of new protein formation within muscles. Leucine acts as a key regulator by activating mTORC1, which increases translation initiation and ribosome biogenesis necessary for building new proteins[1][3]. Supplementation with EAAs has been shown to enhance net positive protein balance after exercise and can help mitigate age-related sarcopenia or disease-associated wasting[4][5]. Because this entry refers broadly to a biological process rather than a discrete molecular entity that can be directly targeted by drugs in the conventional sense (such as receptors or enzymes), it should not be considered a canonical therapeutic target. > "A deficiency or imbalance in essential amino acids can impede protein synthesis... Leucine... has emerged as a key regulator of the mammalian target of rapamycin (mTOR) signaling pathway..." [1][3] > "Essential amino acid-based compositions containing high proportions of leucine have become appreciated for stimulation of muscle protein synthesis..." [5] In summary: this entry describes an important physiological mechanism but does not correspond to an individual molecular drug target; therefore it is classified as incorrect under standard nomenclature conventions for drug targets.
Activation of the mTOR signaling pathway by leucine and other essential amino acids, leading to increased translation initiation and ribosomal assembly for new protein synthesis[1][3][5].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Essential amino acid-mediated muscle protein synthesis.